Skip to main content

Advertisement

SpringerLink
Log in

Clozapine-induced sialorrhea: pathophysiology and management strategies

  • Review
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Clozapine is an atypical antipsychotic agent with proven efficacy in refractory schizophrenia, but its widespread use is limited by adverse effects such as agranulocytosis, seizures, sedation, weight gain, and sialorrhea. Clozapine-induced sialorrhea (CIS) is bothersome and has socially stigmatizing adverse effects, which result in poor treatment compliance. The pathophysiology of this condition is poorly understood and the treatment options available are based mostly on case reports and open-label studies.

Objective

To review the available studies on CIS.

Method

All relevant studies available through PUBMED search supplemented with manual search were undertaken.

Result

The clinical features, complications, assessment, pathophysiology, and management of CIS are discussed.

Conclusion

Although the studies evaluating the therapeutic options has limitations and no drug has been found to be superior, judicious use of pharmacological agents along with behavioral methods will reduce this troublesome side effect and enhance compliance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ahlner BH, Lind MG (1983) A swab technique for sialometry. Normal range. Acta Otolaryngol 95(1–2):173–182

    PubMed  Google Scholar 

  • Antonello C, Tessier P (1999) Clozapine and sialorrhea: a new intervention for this bothersome and potentially dangerous side effect. J Psychiatry Neurosci 24:250

    PubMed  Google Scholar 

  • Bai YM, Lin CC, Chen JY, Liu WC (2001) Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Psychopharmacol 21(6):608–611

    Article  PubMed  Google Scholar 

  • Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM (1992) Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 160:12–16

    PubMed  Google Scholar 

  • Ben-Areyh H, Jungeman T, Szargel R, Klein E, Laufer D (1996) Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data. Biol Psychiatry 39:946–949

    Article  PubMed  Google Scholar 

  • Berlan M, Montrstruc J, Lafontan M (1992) Pharmacological prospects for alpha 2 adrenoceptor antagonist therapy. Trends Pharmacol Sci 13:277–282

    Article  PubMed  Google Scholar 

  • Bothwell JE, Clarke K, Dooley JM et al (2002) Botulinum toxin A as a treatment for excessive drooling in children. Pediatr Neurol 27:18–22

    Article  PubMed  Google Scholar 

  • Bourgeois JA, Drexler KG, Hall MJ (1991) Hypersalivation and clozapine. Hosp Community Psychiatry 42(11):1174

    PubMed  Google Scholar 

  • Boyce HW, Bakheet MR (2005) Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. J Clin Gastroenterol 39(2):89–97

    PubMed  Google Scholar 

  • Brodkin ES, Pelton GH, Price LH (1996) Treatment of clozapine-induced parotid gland swelling. Am J Psychiatry 153:445

    Google Scholar 

  • Calderon J, Robin E, Sobota WL (2000) Potential use of ipratropium bromide for the treatment of clozapine induced hypersalivation: a preliminary report. Int Clin Psychopharmacol 15:49–52

    PubMed  Google Scholar 

  • Carlson GW (2000) The salivary glands. Embryology, anatomy, and surgical applications. Surg Clin North Am 80:261–273

    Article  PubMed  Google Scholar 

  • Chatelut E, Rispail Y, Berlan M et al (1989) Yohimbine increases human salivary secretion. Br J Clin Pharmacol 28:366–368

    PubMed  Google Scholar 

  • Comley C, Galletly C, Ash D (2000) Use of atropine eye drops for clozapine induced hypersalivation. Aust N Z J Psychiatry 34(6):1033–1034

    Article  PubMed  Google Scholar 

  • Copp PJ, Lament R, Tennent TG (1991) Amitriptyline in clozapine-induced sialorrhea. Br J Psychiatry 159:166

    Google Scholar 

  • Corrigan FM, MacDonald S (1995) Clozapine-induced hypersalivation and the alpha 2 adrenoceptor. Br J Psychiatry 167:412

    Google Scholar 

  • Cree A, Mir S, Fahy T (2001) A review of the treatment options for clozapine-induced hypersalivation. Psychiatr Bull 25:114–116

    Article  Google Scholar 

  • Croissant B, Hermann D, Olbrich R (2005) Reduction of side effects by combining clozapine with amisulpride: case report and short review of clozapine-induced hypersalivation. Pharmacopsychiatry 38:38–39

    Article  PubMed  Google Scholar 

  • Davydov L, Botts SR (2000) Clozapine-induced hypersalivation. Ann Pharmacother 34(5):662–665

    Article  PubMed  Google Scholar 

  • Disse B, Reichl R, Speck G et al (1993) Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 52:537–544

    Article  PubMed  Google Scholar 

  • Frankenburg AE (1991) Clozapine update. Tufts University School of Medicine, Ninth Annual Psychopharmacology Update, Boston

  • Freudenreich O, Beebe M, Goff DC (2004) Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series. J Clin Psychopharmacol 24(1):98–100

    Article  PubMed  Google Scholar 

  • Fritze J, Elliger T (1995) Pirenzepine for clozapine-induced hypersalivation. Lancet 346:1034

    Article  Google Scholar 

  • Gaftanyuk O, Trestman RL (2004) Scolpolamine patch for clozapine-induced sialorrhea. Psychiatr Serv 55(3):318

    Article  Google Scholar 

  • Grabowski J (1992) Clonidine treatment of clozapine-induced hypersalivation. J Clin Psychopharmacol 12(1):69–70

    PubMed  Google Scholar 

  • Gross NJ (1988) Ipratropium bromide. N Engl J Med 319:486–494

    PubMed  Google Scholar 

  • Gross NJ (2004) Tiotropium bromide. Chest 126:1946–1953

    Article  PubMed  Google Scholar 

  • Harris MM, Dignam PF (1980) A nonsurgical method of reducing drooling in cerebral-palsied children. Dev Med Child Neurol 22(3):293–299

    PubMed  Google Scholar 

  • Hinkes R, Quesada TV, Currier MB, Gonzalez-Blanco M (1996) Aspiration pneumonia secondary to clozapine-induced sialorrhea. Br J Psychiatry 169(3):390–391

    Google Scholar 

  • Hyson HC, Johnson AM, Jog MS (2002) Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 17(6):1318–1320

    Article  PubMed  Google Scholar 

  • Ichikawa J, Dai J, O’Laughlin IA et al (2002) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26:325–339

    Article  PubMed  Google Scholar 

  • Jongerius PH, van Limbeek J, Rotteveel JJ (2004) Assessment of salivary flow rate: biologic variation and measure error. Laryngoscope 114:1801–1804

    Article  PubMed  Google Scholar 

  • Kahl KG, Hagenah J, Zapf S, Trillenberg P, Klein C, Lencer R (2004) Botulinum toxin as an effective treatment of clozapine-induced hypersalivation. Psychopharmacology (Berl) 173(1–2):229–230

    Article  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine. Arch Gen Psychiatry 45:789–796

    PubMed  Google Scholar 

  • Lieberman JA, Safferman AZ (1992) Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 63(1):51–70

    Article  PubMed  Google Scholar 

  • Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G (2003) A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61(9):1279–1281

    PubMed  Google Scholar 

  • Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G et al (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18(6):685–688

    Article  PubMed  Google Scholar 

  • Mandel ID, Zengo A, Katz R, Wotman S (1975) Effect of adrenergic agents on salivary composition. J Dent Res 54:B27–B33

    PubMed  Google Scholar 

  • Marinkovic D, Timotijevic I, Babinski T et al (1994) The side effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 18:537–544

    Article  PubMed  Google Scholar 

  • McCarthy R, Terkelsen K (1994) Oesophageal dysfunction in two patients after clozapine treatment. J Clin Psychopharmacol 14:281–283

    PubMed  Google Scholar 

  • McKane JP, Hall C, Akram G (2001) Hyoscine patches in clozapine induced hypersalivation. Psychiatr Bull 25:277

    Article  Google Scholar 

  • Michal P, Lysikova M, El-Fakahany EE, Tucek S (1999) Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors. Eur J Pharmacol 376(1–2):119–125

    Article  PubMed  Google Scholar 

  • Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M (2000) Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. Arch Pediatr Adolesc Med 154:1214–1218

    PubMed  Google Scholar 

  • Navazesh M, Christensen CM (1982) A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res 61:1158–1162

    PubMed  Google Scholar 

  • Nemeroff CB, Putnam JS (2005) α2-Adrenergic receptor agonists: clonidine and guanfacine. In: Sadock BJ, Sadock VA (eds) Kaplan & Sadock’s comprehensive textbook of psychiatry, vol. 2. Lippincot Williams & Wilkins, Philadelphia, pp 2718–2722

    Google Scholar 

  • Newall AR, Orser R, Hunt M (1996) The control of oral secretions in bulbar ALS/MND. J Neurol Sci 139(suppl):43–44

    Article  PubMed  Google Scholar 

  • Ogura C, Kishimoto A, Mizukawa R (1987) Comparative study of the effects of 9 antidepressants on several physiological parameters in healthy volunteers. Neuropsychobiology 17:139–144

    PubMed  Google Scholar 

  • Pearlman C (1994) Clozapine, nocturnal sialorrhea, and choking. J Clin Psychopharmacol 14(4):283

    PubMed  Google Scholar 

  • Pitcher JL (1971) Safety and effectiveness of the modified Sengstaken–Blakemore tube: a prospective study. Gastroenterology 61:291–298

    PubMed  Google Scholar 

  • Praharaj SK, Verma P, Roy D, Singh A (2005) Is clonidine useful for treatment of clozapine-induced sialorrhea? J Psychopharmacol 19(4):426–428

    Article  PubMed  Google Scholar 

  • Rabinowitz T, Frankenburg FR, Centorrino F, Kando J (1996) The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiatry 40:1132–1134

    Article  PubMed  Google Scholar 

  • Rapp D (1980) Drool control: long-term follow-up. Dev Med Child Neurol 22:448–453

    PubMed  Google Scholar 

  • Reddihough D, Johnson H, Ferguson E (1992) The role of a saliva control clinic in the management of drooling. J Paediatr Child Health 28:395–397

    PubMed  Google Scholar 

  • Reinstein MJ, Sirotovskaya LA, Chasanov MA, Jones LE (1999) Comparative efficacy and tolerability of benztropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clin Drug Investig 17(2):97–102

    Article  Google Scholar 

  • Richardson C, Kelly DL, Conley RR (2001) Biperiden for excessive sweating from clozapine. Am J Psychiatry 158:1329–1330

    Article  Google Scholar 

  • Richelson E, Nelson A (1984) Antagonism by neuroleptics of neurotransmitter of normal brain in vitro. Eur J Pharmacol 103:197–204

    Article  PubMed  Google Scholar 

  • Robinson D, Fenn H, Yesavage J (1995) Possible association of parotitis with clozapine. Am J Psychiatry 152(2):297–298

    PubMed  Google Scholar 

  • Rogers D, Shramko J (2000) Therapeutic options in the treatment of clozapine-induced sialorrhoea. Pharmacotherapy 20(9):1092–1095

    Article  PubMed  Google Scholar 

  • Rotteveel LJC, Jongerius PH, van Limbeek J, van den Hoogen FJA (2004) Salivation in healthy school children. Int J Pediatr Otorhinolaryngol 68(6):767–774

    Article  PubMed  Google Scholar 

  • Safferman A, Liberman J, Kane M et al (1991) Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 17:247–261

    PubMed  Google Scholar 

  • Sanchez C, Lembol HL (1994) The involvement of muscarinic receptor subtypes in the mediation of hypothermia, tremor, and salivation in male mice. Pharmacol Toxicol 74(1):35–39

    PubMed  Google Scholar 

  • Schneider B, Weigmann H, Hiemke C, Weber B, Fritze J (2004) Reduction of clozapine-induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry 37(2):43–45

    Article  PubMed  Google Scholar 

  • Senner JE, Logemann J, Zecker S, Gaebler-Spira D (2004) Drooling, saliva production, and swallowing in cerebral palsy. Dev Med Child Neurol 46(12):801–806

    Article  PubMed  Google Scholar 

  • Sochaniwskyj AE (1982) Drool quantification: noninvasive technique. Arch Phys Med Rehabil 63:605–607

    PubMed  Google Scholar 

  • Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A (1996) Trihexyphenidyl treatment of clozapine-induced hypersalivation. J Clin Psychopharmacol 16:462–463

    Article  PubMed  Google Scholar 

  • Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A (1997) Trihexyphenidyl treatment of clozapine-induced hypersalivation. Int Clin Psychopharmacol 12(4):213–215

    PubMed  Google Scholar 

  • Suskind DL, Tilton A (2002) Clinical study of Botulinum-A toxin in the treatment of sialorrhea with children with cerebral palsy. Laryngoscope 112:73–81

    Article  PubMed  Google Scholar 

  • Szabadi E (1996) Clozapine-induced hypersalivation and the alpha-2 adrenoceptor. Br J Psychiatry 169(3):380–381

    Google Scholar 

  • Szabo B (2002) Imidazoline antihypertensive drugs: critical review on their mechanism of action. Pharmacol Ther 93:1–35

    Article  PubMed  Google Scholar 

  • Taylor D, Paton C, Kerwin R (2003) The South London and Maudsley NHS Trust 2003 prescribing guidelines. Martin Dunitz, London

    Google Scholar 

  • Terry R, Frances RF, Franca C, Judith K (1996) The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiatry 40:1132–1134

    Article  PubMed  Google Scholar 

  • Tessier P, Antonello C (2001) Clozapine and sialorrhea: update. J Psychiatry Neurosci 26(3):253

    Google Scholar 

  • Thomas-Stonell N, Greenberg J (1988) Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 3:73–78

    PubMed  Google Scholar 

  • Thorburn JR, James MF, Feldman C, Moyes DG, Du Toit PS (1986) Comparison of the effects of atropine and glycopyrrolate on pulmonary mechanics in patients undergoing fibreoptic bronchoscopy. Anesth Analg 65:1285–1289

    PubMed  Google Scholar 

  • Tscheng DZ (2002) Sialorrhea—therapeutic drug options. Ann Pharmacother 36(11):1785–1790

    Article  PubMed  Google Scholar 

  • Van Kammen DP, Marder SR (2005) Serotonin–dopamine antagonists (atypical or second generation antipsychotics). In: Sadock BJ, Sadock VA (eds) Kaplan & Sadock’s comprehensive textbook of psychiatry, vol. 2. Lippincot Williams & Wilkins, Philadelphia, pp 2914–2938

    Google Scholar 

  • Vasile JS, Steingard S (1995) Clozapine and the development of salivary gland swelling: a case study. J Clin Psychiatry 56(11):511–513

    PubMed  Google Scholar 

  • Wagstaff AJ, Bryson HM (1995) Clozapine: a review of its pharmacological properties and a therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1:370–400

    Google Scholar 

  • Wagstaff A, Perry C (2003) Clozapine: in prevention of suicide in patients with schizophrenia or schizo-affective disorder. CNS Drugs 17(4):273–280 (discussion 281–283)

    Article  PubMed  Google Scholar 

  • Webber MA, Szwast SJ, Steadman TM, Frazer A, Malloy FW, Lightfoot JD et al (2004) Guanfacine treatment of clozapine-induced sialorrhea. J Clin Psychopharmacol 24(6):675–676

    Article  PubMed  Google Scholar 

  • Young CR, Bowers MB, Mazure CM (1998) Management of the adverse effects of clozapine. Schizophr Bull 24:381–390

    PubMed  Google Scholar 

  • Zeppetella G (1999) Nebulized scopolamine in the management of oral dribbling: three case reports. J Pain Symptom Manage 17(4):293–295

    Article  PubMed  Google Scholar 

  • Zorn SH, Jones SB, Ward KM, Liston DR (1994) Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 269:R1–R2

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Central Institute of Psychiatry, Ranchi, Jharkhand, 864006, India

    Samir Kumar Praharaj, Manu Arora & Sachin Gandotra

Authors
  1. Samir Kumar Praharaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manu Arora
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sachin Gandotra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samir Kumar Praharaj.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Praharaj, S.K., Arora, M. & Gandotra, S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology 185, 265–273 (2006). https://doi.org/10.1007/s00213-005-0248-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-005-0248-4

Keywords

Search

Navigation